Paper39450552
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W and 6 others. Int J Mol Med, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review). Papers, record 39450552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39450552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Precision Medicine | Major topic |
| Mutation | Major topic |
| Humans | |
| Female | |
| Biomarkers, Tumor | |
| Molecular Targeted Therapy |
Source PubMed
References141
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31756919 | Immunotherapy: A Challenge of Breast Cancer Treatment. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31756919 | PubMed |
| 2 | 22862954 | First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. | J Transl Med | 2012 | https://conductscience.org/library/papers/22862954 | PubMed |
| 3 | 12960733 | Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin. | Anticancer Drugs | 2003 | https://conductscience.org/library/papers/12960733 | PubMed |
| 4 | 22068656 | A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/22068656 | PubMed |
| 5 | 29236940 | Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. | Ann Oncol | 2018 | https://conductscience.org/library/papers/29236940 | PubMed |
| 6 | 38244459 | "Heterogeneity of treatment effect on patients' long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer." | Breast | 2024 | https://conductscience.org/library/papers/38244459 | PubMed |
| 7 | 38193640 | Mutational profiling of mitochondrial DNA reveals an epithelial ovarian cancer-specific evolutionary pattern contributing to high oxidative metabolism. | Clin Transl Med | 2024 | https://conductscience.org/library/papers/38193640 | PubMed |
| 8 | 11839652 | Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I/II trial. | Clin Cancer Res | 2002 | https://conductscience.org/library/papers/11839652 | PubMed |
| 9 | 23819870 | Identifying Mendelian disease genes with the variant effect scoring tool. | BMC Genomics | 2013 | https://conductscience.org/library/papers/23819870 | PubMed |
| 10 | 19244125 | Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. | Cancer Res | 2009 | https://conductscience.org/library/papers/19244125 | PubMed |
| 11 | 33893808 | MutationTaster2021. | Nucleic Acids Res | 2021 | https://conductscience.org/library/papers/33893808 | PubMed |
| 12 | 34507558 | Comprehensive analysis of the cancer driver genes in breast cancer demonstrates their roles in cancer prognosis and tumor microenvironment. | World J Surg Oncol | 2021 | https://conductscience.org/library/papers/34507558 | PubMed |
| 13 | 28274957 | An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28274957 | PubMed |
| 14 | 3821953 | [A different form for the certification of cause of death]. | Ned Tijdschr Geneeskd | 1986 | https://conductscience.org/library/papers/3821953 | PubMed |
| 15 | 28650338 | IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | J Clin Invest | 2017 | https://conductscience.org/library/papers/28650338 | PubMed |
| 16 | 30546008 | Immune checkpoint inhibitors: recent progress and potential biomarkers. | Exp Mol Med | 2018 | https://conductscience.org/library/papers/30546008 | PubMed |
| 17 | 22130160 | A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. | J Immunother | 2012 | https://conductscience.org/library/papers/22130160 | PubMed |
| 18 | 37239898 | Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37239898 | PubMed |
| 19 | 23801303 | Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. | Invest New Drugs | 2013 | https://conductscience.org/library/papers/23801303 | PubMed |
| 20 | 30674894 | Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer. | Nat Commun | 2019 | https://conductscience.org/library/papers/30674894 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42649570 | Integrated RNA Sequencing and Multi-Bioinformatics Analyses Reveal the Molecular Mechanisms Underlying the Anti-Breast Cancer Effects of the Fritillariae Thunbergii Bulbus-Bolbostemmatis Rhizoma Herb Pair. | Cell Biochem Funct | 2026 | https://conductscience.org/library/papers/42649570 | PubMed |
| 42265489 | Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42265489 | PubMed |
| 41979751 | Mean platelet volume-to-albumin ratio as a predictor of pathological complete response in HER2-positive breast cancer undergoing neoadjuvant chemotherapy. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41979751 | PubMed |
| 41764124 | Crosstalk between mitophagy and breast cancer: mechanisms of action and clinical applications. | J Cancer Res Clin Oncol | 2026 | https://conductscience.org/library/papers/41764124 | PubMed |
| 40407592 | Building a Hand-Curated ceRNET for Endometrial Cancer, Striving for Clinical as Well as Medicolegal Soundness: A Systematic Review. | Noncoding RNA | 2025 | https://conductscience.org/library/papers/40407592 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39450552
GET https://conductscience.org/api/papers/v1/39450552/references?page=2